350 related articles for article (PubMed ID: 35904151)
1. Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.
Johnson SA; Burke KM; Scheier ZA; Keegan MA; Clark AP; Chan J; Fournier CN; Berry JD
Muscle Nerve; 2022 Oct; 66(4):495-502. PubMed ID: 35904151
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
[TBL] [Abstract][Full Text] [Related]
3. Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale.
Sun C; Fournier CN; Ye S; Zhang N; Ma Y; Fan D
Eur J Neurol; 2021 Jun; 28(6):1876-1883. PubMed ID: 33686758
[TBL] [Abstract][Full Text] [Related]
4. Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R.
Fournier CN; James V; Glass JD
Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):311-316. PubMed ID: 36476010
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers.
Manera U; Solero L; Fournier CN; Canosa A; Vasta R; Bombaci A; Grassano M; Palumbo F; Torrieri MC; Salamone P; Casale F; Fuda G; Moglia C; Calvo A; Chiò A
Amyotroph Lateral Scler Frontotemporal Degener; 2022 Aug; 23(5-6):424-429. PubMed ID: 34894916
[No Abstract] [Full Text] [Related]
6. Remote digital assessment of amyotrophic lateral sclerosis functional rating scale - a multicenter observational study.
Meyer T; Spittel S; Grehl T; Weyen U; Steinbach R; Kettemann D; Petri S; Weydt P; Günther R; Baum P; Schlapakow E; Koch JC; Boentert M; Wolf J; Grosskreutz J; Rödiger A; Ilse B; Metelmann M; Norden J; Koc RY; Körtvélyessy P; Riitano A; Walter B; Hildebrandt B; Schaudinn F; Münch C; Maier A
Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):175-184. PubMed ID: 35912984
[TBL] [Abstract][Full Text] [Related]
7. Assessing the Measurement Properties of the Self-Administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): A Rasch Analysis.
Mehdipour A; Teshler L; Dal Bello-Haas V; Richardson J; Beauchamp M; Turnbull J; Chum M; Johnston W; O'Connell C; Luth W; Kuspinar A
Phys Ther; 2023 Nov; 103(11):. PubMed ID: 37581600
[TBL] [Abstract][Full Text] [Related]
8. Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures.
Johnson SA; Karas M; Burke KM; Straczkiewicz M; Scheier ZA; Clark AP; Iwasaki S; Lahav A; Iyer AS; Onnela JP; Berry JD
NPJ Digit Med; 2023 Mar; 6(1):34. PubMed ID: 36879025
[TBL] [Abstract][Full Text] [Related]
9. Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.
Young CA; Chaouch A; Mcdermott CJ; Al-Chalabi A; Chhetri SK; Talbot K; Malaspina A; Mills R; Tennant A
Amyotroph Lateral Scler Frontotemporal Degener; 2024 May; 25(3-4):400-409. PubMed ID: 38426231
[TBL] [Abstract][Full Text] [Related]
10. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
11. Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale.
Chew S; Burke KM; Collins E; Church R; Paganoni S; Nicholson K; Babu S; Scalia JB; De Marchi F; Ellrodt AL; Moura LMVR; Chan J; Berry JD
Amyotroph Lateral Scler Frontotemporal Degener; 2021 Nov; 22(7-8):467-477. PubMed ID: 33771057
[No Abstract] [Full Text] [Related]
12. Longitudinal comparison of the self-administered ALSFRS-RSE and ALSFRS-R as functional outcome measures in ALS.
Erb MK; Calcagno N; Brown R; Burke KM; Scheier ZA; Iyer AS; Clark A; Higgins MP; Keegan M; Gupta AS; Johnson SA; Chew S; Berry JD
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Mar; ():1-11. PubMed ID: 38501453
[No Abstract] [Full Text] [Related]
13. Do we really need to calculate a minimal important difference for ALSFRS-R?: A letter in response to 'Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R' published in Vol. 24(3-4), pp. 311-316.
Vázquez-Costa JF
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):214-215. PubMed ID: 37647208
[No Abstract] [Full Text] [Related]
14. Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS): validation and longitudinal performance.
Fortuna A; Sabbatini D; Frigo A; Bello L; Calvi F; Blasi L; Gianferrari G; Martinelli I; Minicuci G; Pegoraro E; Mandrioli J; Sorarù G
J Neurol; 2023 Mar; 270(3):1452-1456. PubMed ID: 36383259
[TBL] [Abstract][Full Text] [Related]
15. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.
Hu N; Shen D; Yang X; Cui L; Liu M
Acta Neurol Belg; 2022 Dec; 122(6):1567-1573. PubMed ID: 35034333
[TBL] [Abstract][Full Text] [Related]
16. Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS.
de Jongh AD; van Eijk RPA; Bakker LA; Bunte TM; Beelen A; van der Meijden C; van Es MA; Visser-Meily JMA; Kruitwagen ET; Veldink JH; van den Berg LH
Neurology; 2023 Aug; 101(6):e602-e612. PubMed ID: 37311649
[TBL] [Abstract][Full Text] [Related]
17. Qualitative measures that assess functional disability and quality of life in ALS.
Hartmaier SL; Rhodes T; Cook SF; Schlusser C; Chen C; Han S; Zach N; Murthy V; Davé S
Health Qual Life Outcomes; 2022 Jan; 20(1):12. PubMed ID: 35062955
[TBL] [Abstract][Full Text] [Related]
18. Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice.
Ludolph AC; Corcia P; Desnuelle C; Heiman-Patterson T; Mora JS; Mansfield CD; Couratier P
Muscle Nerve; 2024 Jul; 70(1):36-41. PubMed ID: 38712849
[TBL] [Abstract][Full Text] [Related]
19. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale).
Smith RA; Macklin EA; Myers KJ; Pattee GL; Goslin KL; Meekins GD; Green JR; Shefner JM; Pioro EP
Eur J Neurol; 2018 Jul; 25(7):907-e66. PubMed ID: 29577526
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
